The positive data on Tafasitamab (Monjuvi®) presented at a major conference like ASH 2024 is likely to enhance investor sentiment and could lead to a short-term increase in Incyte's stock price. The improvement in progression-free survival is a significant clinical outcome that may drive interest and investment in the company.